Table of Content

"1    INTRODUCTION    30
1.1    OBJECTIVES OF THE STUDY    30
1.2    MARKET DEFINITION    30
1.2.1    INCLUSIONS & EXCLUSIONS OF THE STUDY    31
1.3    MARKET SCOPE    32
1.3.1    MARKETS COVERED    32
1.3.2    YEARS CONSIDERED FOR THE STUDY    33
1.4    CURRENCY USED FOR THE STUDY    33
1.5    MAJOR MARKET STAKEHOLDERS    33
1.6    SUMMARY OF CHANGES    34
2    RESEARCH METHODOLOGY    35
2.1    RESEARCH DATA    35
FIGURE 1    RESEARCH DESIGN    35
2.1.1    SECONDARY DATA SOURCES    36
2.1.1.1    Indicative list of secondary sources    37
2.1.2    PRIMARY DATA SOURCES    37
FIGURE 2    BREAKDOWN OF PRIMARIES: SEPSIS DIAGNOSTICS MARKET    38
2.2    MARKET ESTIMATION METHODOLOGY    38
FIGURE 3    RESEARCH METHODOLOGY: HYPOTHESIS BUILDING    39
2.2.1    REVENUE MAPPING-BASED MARKET ESTIMATION    39
2.2.1.1    Procedure-based market estimation    39
FIGURE 4    MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY    40
FIGURE 5    MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON REVENUE MAPPING METHODOLOGY    41
2.2.2    PRIMARY RESEARCH VALIDATION    41
2.3    DATA TRIANGULATION    42
FIGURE 6    DATA TRIANGULATION METHODOLOGY    42
2.4    RESEARCH ASSUMPTIONS    43
2.5    RESEARCH LIMITATIONS    43
3    EXECUTIVE SUMMARY    44
FIGURE 7    SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)    44
FIGURE 8    SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION)    45
FIGURE 9    SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2021 VS. 2026 (USD MILLION)    45
FIGURE 10    SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2021 VS. 2026 (USD MILLION)    46
FIGURE 11    SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN,
2021 VS. 2026 (USD MILLION)    47
FIGURE 12    SEPSIS DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION)    47
FIGURE 13    GEOGRAPHICAL SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET    48
4    PREMIUM INSIGHTS    49
4.1    SEPSIS DIAGNOSTICS MARKET OVERVIEW    49
FIGURE 14    THE RISING INCIDENCE OF SEPSIS AND THE RISING NUMBER OF HOSPITAL-ACQUIRED INFECTIONS ARE KEY FACTORS DRIVING THE MARKET GROWTH    49
4.2    SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)    50
FIGURE 15    MOLECULAR DIAGNOSTICS TO REGISTER THE HIGHEST GROWTH IN THE SEPSIS DIAGNOSTICS MARKET DURING THE FORECAST PERIOD    50
4.3    SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2021 VS. 2026 (USD MILLION)    51
FIGURE 16    CONVENTIONAL DIAGNOSTICS IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET, BY METHOD, DURING THE FORECAST PERIOD    51
4.4    ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2021)    52
FIGURE 17    BLOOD CULTURE MEDIA SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET FOR APAC    52
4.5    GEOGRAPHIC SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET    53
FIGURE 18    APAC MARKET TO WITNESS THE HIGHEST GROWTH DURING
THE FORECAST PERIOD (2021–2026)    53
5    MARKET OVERVIEW    54
5.1    INTRODUCTION    54
5.2    MARKET DYNAMICS    54
FIGURE 19    SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    54
5.2.1    DRIVERS    55
5.2.1.1    High incidence of sepsis    55
5.2.1.2    Rising incidence of hospital-acquired infections    56
5.2.1.3    Growing funding for sepsis-related research    56
5.2.2    RESTRAINTS    57
5.2.2.1    High cost of automated diagnostic devices    57
5.2.3    OPPORTUNITIES    57
5.2.3.1    Development of rapid diagnostic/POC techniques for early sepsis diagnosis    57
5.2.3.2    Evolution of novel biomarkers for sepsis diagnosis    57
5.2.3.3    Growth opportunities in emerging economies    58
5.2.4    CHALLENGES    58
5.2.4.1    Lack of awareness and limited protocols for sepsis diagnosis    58
5.2.4.2    Shortage of skilled healthcare professionals    59

5.3    REGULATORY LANDSCAPE    59
5.3.1    NORTH AMERICA    59
5.3.1.1    US    59
5.3.1.2    Canada    59
5.3.2    EUROPE    60
5.3.3    ASIA PACIFIC    60
5.3.3.1    China    60
5.3.3.2    Japan    60
5.3.3.3    India    60
5.3.4    LATIN AMERICA    61
5.4    PATENT ANALYSIS    61
FIGURE 20    TOP 10 PATENT APPLICANTS FOR SEPSIS DIAGNOSTICS
(JANUARY 2011 TO DECEMBER 2021)    61
FIGURE 21    NUMBER OF GRANTED PATENT AND PATENT APPLICATIONS FILED BY APPLICATIONS (JANUARY 2011 TO DECEMBER 2021)    62
FIGURE 22    PATENT DOCUMENTS FOR SEPSIS DIAGNOSTICS, BY LEGAL STATUS (JANUARY 2011 TO DECEMBER 2021)    62
FIGURE 23    REGIONAL ANALYSIS OF PATENTS GRANTED FOR SEPSIS DIAGNOSTICS (JANUARY 2011 TO DECEMBER 2021)    63
5.5    COVID-19 IMPACT ON THE SEPSIS DIAGNOSTICS MARKET    63
5.6    VALUE CHAIN ANALYSIS    64
FIGURE 24    VALUE CHAIN OF THE SEPSIS DIAGNOSTICS MARKET    64
5.7    PRICING TREND ANALYSIS    65
TABLE 1    AVERAGE PRICE OF SEPSIS DIAGNOSTICS BLOOD CULTURE MEDIA, ASSAYS & REAGENT KITS AND EQUIPMENT, BY COUNTRY, 2020 (USD)    65
5.8    REIMBURSEMENT SCENARIO    65
TABLE 2    MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS    66
5.9    PORTER’S FIVE FORCES ANALYSIS    66
TABLE 3    SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS    66
5.9.1    THREAT OF NEW ENTRANTS    67
FIGURE 25    THREAT OF NEW ENTRANTS    67
5.9.2    THREAT OF SUBSTITUTES    68
FIGURE 26    THREAT OF SUBSTITUTES    68
5.9.3    BARGAINING POWER OF SUPPLIERS    68
FIGURE 27    BARGAINING POWER OF SUPPLIERS    68
5.9.4    BARGAINING POWER OF BUYERS    69
FIGURE 28    BARGAINING POWER OF BUYERS    69
5.9.5    INTENSITY OF COMPETITIVE RIVALRY    69
FIGURE 29    INTENSITY OF COMPETITIVE RIVALRY    70
5.10    ECOSYSTEM COVERAGE    70

6    SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY    71
6.1    INTRODUCTION    72
TABLE 4    SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    72
6.2    BLOOD CULTURE (MICROBIOLOGY TESTING)    72
6.2.1    BLOOD CULTURE IS THE MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS    72
TABLE 5    BLOOD CULTURE MARKET, BY REGION, 2019–2026 (USD MILLION)    73
TABLE 6    BLOOD CULTURE MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    73
TABLE 7    BLOOD CULTURE MARKET, BY METHOD, 2019–2026 (USD MILLION)    73
TABLE 8    BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    74
TABLE 9    BLOOD CULTURE MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    74
TABLE 10    BLOOD CULTURE MARKET, BY END USER, 2019–2026(USD MILLION)    74
6.3    IMMUNOASSAYS    75
6.3.1    PRODUCT DEVELOPMENT BY MAJOR PLAYERS HAS ENSURED
 THE DEMAND FOR IMMUNOASSAYS    75
TABLE 11    IMMUNOASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)    75
TABLE 12    IMMUNOASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    76
TABLE 13    IMMUNOASSAYS MARKET, BY METHOD, 2019–2026 (USD MILLION)    76
TABLE 14    IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    76
TABLE 15    IMMUNOASSAYS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    77
TABLE 16    IMMUNOASSAYS DIAGNOSTICS MARKET, BY END USER,
 2019–2026(USD MILLION)    77
6.4    MOLECULAR DIAGNOSTICS    77
TABLE 17    MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026(USD MILLION)    78
TABLE 18    MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION)    78
TABLE 19    MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    78
TABLE 20    MOLECULAR DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION)    79
TABLE 21    MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION)    79
TABLE 22    MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)    79
TABLE 23    MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION)    80
6.4.1    POLYMERASE CHAIN REACTION (PCR)    80
6.4.1.1    Quick turnaround time, coupled with technological advancements to increase the adoption of PCR for sepsis diagnosis    80
TABLE 24    PCR MARKET, BY REGION, 2019–2026 (USD MILLION)    80
TABLE 25    PCR MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    81
TABLE 26    PCR MARKET, BY METHOD, 2019–2026 (USD MILLION)    81
TABLE 27    PCR MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    81
TABLE 28    PCR MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    82
TABLE 29    PCR MARKET, BY END USER, 2019–2026(USD MILLION)    82
6.4.2    DNA MICROARRAYS    82
6.4.2.1    Simultaneous analysis capabilities & accuracy have driven
 the use of microarrays    82
TABLE 30    DNA MICROARRAYS MARKET, BY REGION, 2019–2026 (USD MILLION)    83
TABLE 31    DNA MICROARRAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    83
TABLE 32    DNA MICROARRAYS MARKET, BY METHOD, 2019–2026 (USD MILLION)    83
TABLE 33    DNA MICROARRAYS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION)    84
TABLE 34    DNA MICROARRAYS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    84
TABLE 35    DNA MICROARRAYS MARKET, BY END USER, 2019–2026(USD MILLION)    84
6.4.3    PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION (PNA-FISH)    85
6.4.3.1    PNA-FISH kits allow for the rapid diagnosis
of bloodstream infections (BSIs)    85
TABLE 36    PNA-FISH MARKET, BY REGION, 2019–2026 (USD MILLION)    85
TABLE 37    PNA-FISH MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    85
TABLE 38    PNA-FISH MARKET, BY METHOD, 2019–2026 (USD MILLION)    86
TABLE 39    PNA-FISH MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    86
TABLE 40    PNA-FISH MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    86
TABLE 41    PNA-FISH MARKET, BY END USER, 2019–2026(USD MILLION)    87
6.4.4    DNA SEQUENCING    87
6.4.4.1    DNA Sequencing shortens the time for sepsis diagnosis,
and NGS has applications in COVID-19 diagnosis    87
TABLE 42    DNA SEQUENCING, BY REGION, 2019–2026 (USD MILLION)    88
TABLE 43    DNA SEQUENCING MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    88
TABLE 44    DNA SEQUENCING MARKET, BY METHOD, 2019–2026 (USD MILLION)    88
TABLE 45    DNA SEQUENCING MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    89
TABLE 46    DNA SEQUENCING MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    89
TABLE 47    DNA SEQUENCING MARKET, BY END USER, 2019–2026(USD MILLION)    89
6.4.5    SYNDROMIC PANEL-BASED TESTING    90
6.4.5.1    High costs and accuracy errors limit the adoption
of syndromic-panel-based tests    90
TABLE 48    SYNDROMIC PANEL-BASED TESTING MARKET, BY REGION,
2019–2026 (USD MILLION)    90
TABLE 49    SYNDROMIC PANEL-BASED TESTING MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    90
TABLE 50    SYNDROMIC PANEL-BASED TESTING MARKET, BY METHOD,
2019–2026 (USD MILLION)    91
TABLE 51    SYNDROMIC PANEL-BASED TESTING MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION)    91
TABLE 52    SYNDROMIC PANEL-BASED TESTING MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)    91
TABLE 53    SYNDROMIC PANEL-BASED TESTING MARKET, BY END USER,
2019–2026(USD MILLION)    92
6.5    FLOW CYTOMETRY    92
6.5.1    LACK OF STANDARDIZED PROTOCOLS IS A KEY
RESTRAINT IN FLOW CYTOMETRY    92
TABLE 54    FLOW CYTOMETRY MARKET, BY REGION, 2019–2026 (USD MILLION)    92
TABLE 55    FLOW CYTOMETRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    93
TABLE 56    FLOW CYTOMETRY MARKET, BY METHOD, 2019–2026 (USD MILLION)    93
TABLE 57    FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    93
TABLE 58    FLOW CYTOMETRY MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    94
TABLE 59    FLOW CYTOMETRY MARKET, BY END USER, 2019–2026(USD MILLION)    94
6.6    MICROFLUIDICS    94
6.6.1    RISING ADOPTION OF ADVANCED & RAPID TESTING TO DRIVE THE GROWTH OF THE MICROFLUIDICS SEGMENT    94
TABLE 60    MICROFLUIDICS MARKET, BY REGION, 2019–2026 (USD MILLION)    95
TABLE 61    MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    95
TABLE 62    MICROFLUIDICS MARKET, BY METHOD, 2019–2026 (USD MILLION)    95
TABLE 63    MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    96
TABLE 64    MICROFLUIDICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    96
TABLE 65    MICROFLUIDICS MARKET, BY END USER, 2019–2026(USD MILLION)    96
6.7    BIOMARKERS    97
6.7.1    RESEARCH & DEVELOPMENT FOR THE DISCOVERY OF NOVEL BIOMARKERS TO DRIVE THE GROWTH OF THIS SEGMENT    97
TABLE 66    BIOMARKERS MARKET, BY REGION, 2019–2026 (USD MILLION)    97
TABLE 67    BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    98
TABLE 68    BIOMARKERS MARKET, BY METHOD, 2019–2026 (USD MILLION)    98
TABLE 69    BIOMARKERS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    98
TABLE 70    BIOMARKERS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    99
TABLE 71    BIOMARKERS MARKET, BY END USER, 2019–2026(USD MILLION)    99
7    SEPSIS DIAGNOSTICS MARKET, BY PRODUCT    100
7.1    INTRODUCTION    101
TABLE 72    SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    101
7.2    BLOOD CULTURE MEDIA    101
7.2.1    RISE IN BLOODSTREAM INFECTIONS TO DRIVE THE GROWTH OF BLOOD CULTURE MEDIA IN SEPSIS DIAGNOSIS    101
FIGURE 30    INCIDENCE OF BLOODSTREAM INFECTIONS BY AGE AND SEX, WESTERN INTERIOR OF BRITISH COLUMBIA AND CANADA, 2010–2019    102
TABLE 73    BLOOD CULTURE MEDIA MARKET, BY REGION, 2019–2026 (USD MILLION)    102
7.3    ASSAYS & REAGENT KITS    103
7.3.1    ASSAYS BETTER ENABLE THE ANALYSIS OF PATIENT
SAMPLES FOR DISEASE DIAGNOSIS    103
TABLE 74    ASSAYS & REAGENT KITS MARKET, BY REGION, 2019–2026 (USD MILLION)    103

7.4    INSTRUMENTS    104
7.4.1    TRADITIONAL DIAGNOSTIC INSTRUMENTS ARE GRADUALLY BEING REPLACED BY AUTOMATED INSTRUMENTS    104
TABLE 75    INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)    104
7.5    SOFTWARE    105
7.5.1    RISING USE OF AUTOMATED INSTRUMENTS TO ENSURE THE GROWING DEMAND FOR SOFTWARE    105
TABLE 76    SOFTWARE MARKET, BY REGION, 2019–2026 (USD MILLION)    105
8    SEPSIS DIAGNOSTICS MARKET, BY METHOD    106
8.1    INTRODUCTION    107
TABLE 77    SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019–2026 (USD MILLION)    107
8.1.1    CONVENTIONAL DIAGNOSTICS    107
8.1.1.1    Higher adoption of conventional diagnostics owing to blood culture testing to drive the growth of this segment    107
TABLE 78    CONVENTIONAL DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)    108
8.1.2    AUTOMATED DIAGNOSTICS    108
8.1.2.1    Accuracy & quick turnaround times to drive the adoption of automated diagnostics among medical professionals    108
TABLE 79    AUTOMATED DIAGNOSTICS MARKET, BY REGION,
2019–2026 (USD MILLION)    109
9    SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE    110
9.1    INTRODUCTION    111
TABLE 80    SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION)    111
9.2    BACTERIAL SEPSIS    111
TABLE 81    BACTERIAL SEPSIS MARKET, BY TYPE, 2019–2026 (USD MILLION)    111
9.2.1    GRAM-NEGATIVE BACTERIAL SEPSIS    112
9.2.1.1    Increased proportion of sepsis infection caused by gram-negative bacteria    112
TABLE 82    GRAM-NEGATIVE BACTERIAL CAUSES IN ADULT SEPSIS    112
TABLE 83    GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION,
2019–2026 (USD MILLION)    113
9.2.2    GRAM-POSITIVE BACTERIAL SEPSIS    113
9.2.2.1    Cases of sepsis caused by gram-positive bacteria have
risen in recent years    113
TABLE 84    GRAM-POSITIVE BACTERIAL CAUSES IN ADULT SEPSIS    113
TABLE 85    GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION,
2019–2026 (USD MILLION)    114
9.3    FUNGAL SEPSIS    114
9.3.1    THE RISING INCIDENCE OF FUNGAL HAIS HAS INCREASED THE RISK OF SEPSIS DEVELOPMENT    114
TABLE 86    FUNGAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION)    115

9.4    VIRAL SEPSIS    115
9.4.1    VIRAL PATHOGEN A NEW CAUSATIVE AGENT OF SEPSIS    115
TABLE 87    VIRAL SEPSIS MARKET, BY REGION, 2019–2026 (USD MILLION)    116
9.5    OTHER PATHOGENS    116
TABLE 88    OTHER PATHOGENS MARKET, BY REGION, 2019–2026 (USD MILLION)    116
10    SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE    117
10.1    INTRODUCTION    118
TABLE 89    SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    118
10.2    LABORATORY TESTS    118
10.2.1    LABORATORY TESTS ARE THE MOST COMMON AND
PREFERRED MODE OF TESTING    118
TABLE 90    LABORATORY TEST MARKET FOR SEPSIS DIAGNOSTICS, BY REGION,
2019–2026(USD MILLION)    119
10.3    POINT-OF-CARE TESTS    119
10.3.1    RAPID POC TESTING DRIVES THE GROWTH OF THIS SEGMENT    119
TABLE 91    POC TESTS MARKET FOR SEPSIS DIAGNOSTICS, NY REGION,
2019–2026(USD MILLION)    120
11    SEPSIS DIAGNOSTICS MARKET, BY END USER    121
11.1    INTRODUCTION    122
TABLE 92    SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019–2026(USD MILLION)    122
11.2    HOSPITALS AND SPECIALTY CLINICS    122
11.2.1    INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO BOOST SEGMENT GROWTH    122
TABLE 93    SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECILAITY CLINICS,
BY REGION, 2019–2026 (USD MILLION)    123
11.3    PATHOLOGY & REFERENCE LABORATORIES    123
11.3.1    INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES    123
TABLE 94    SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION)    124
11.4    RESEARCH LABORATORIES AND ACADEMIC INSTITUTES    124
11.4.1    GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION DRIVES THE GROWTH OF THIS SEGMENT    124
TABLE 95    SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION)    125
12    SEPSIS DIAGNOSTICS MARKET, BY REGION    126
12.1    INTRODUCTION    127
12.2    NORTH AMERICA    127
FIGURE 31    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT    127
TABLE 96    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    128
TABLE 97    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    128
TABLE 98    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    129
TABLE 99    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
 2019–2026 (USD MILLION)    129
TABLE 100    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    129
TABLE 101    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)    130
TABLE 102    NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION)    130
12.2.1    US    130
12.2.1.1    Rising incidence of HIAS in us to accelerate the demand for sepsis diagnosis    130
TABLE 103    US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
 2019–2026 (USD MILLION)    132
TABLE 104    US: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
 BY TYPE, 2019–2026 (USD MILLION)    132
12.2.2    CANADA    133
12.2.2.1    The growing availability of sepsis diagnostic products is expected to drive market growth in Canada    133
TABLE 105    CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    134
TABLE 106    CANADA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
 BY TYPE, 2019–2026 (USD MILLION)    134
12.3    EUROPE    135
TABLE 107    EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    135
TABLE 108    EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    136
TABLE 109    EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    136
TABLE 110    EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION)    136
TABLE 111    EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
2019–2026 (USD MILLION)    137
TABLE 112    EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)    137
TABLE 113    EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER,
 2019–2026(USD MILLION)    137
12.3.1    GERMANY    138
12.3.1.1    Growing awareness and the adoption of technologically advanced diagnostics products in Germany to drive the market growth    138
TABLE 114    GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    139
TABLE 115    GERMANY: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    139
12.3.2    UK    139
12.3.2.1    Government support and rising awareness for the early diagnosis of sepsis are the key factors driving market growth in the UK    139
TABLE 116    UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    140
TABLE 117    UK: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    140
12.3.3    FRANCE    141
12.3.3.1    The high incidence of sepsis in France has supported the demand for sepsis diagnostic products    141
TABLE 118    FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
 2019–2026 (USD MILLION)    141
TABLE 119    FRANCE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    142
12.3.4    ITALY    142
12.3.4.1    Limited growth in the healthcare sector to restrain the market growth for sepsis diagnostics in Italy    142
TABLE 120    ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    143
TABLE 121    ITALY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
 BY TYPE, 2019–2026 (USD MILLION)    143
12.3.5    SPAIN    143
12.3.5.1    Rising awareness for the early diagnosis of sepsis to drive the market growth in Spain    143
TABLE 122    SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
 2019–2026 (USD MILLION)    144
TABLE 123    SPAIN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    144
12.3.6    REST OF EUROPE    145
TABLE 124    REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    145
TABLE 125    REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    146
12.4    ASIA PACIFIC    146
TABLE 126    ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    146
TABLE 127    ASIA PACIFIC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    147
TABLE 128    ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
2019–2026 (USD MILLION)    147
TABLE 129    ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION)    147
TABLE 130    ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
 2019–2026 (USD MILLION)    148
TABLE 131    ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)    148
TABLE 132    ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION)    148
12.4.1    JAPAN    149
12.4.1.1    Rising incidence of pneumonia and infectious diseases to support the market growth in Japan    149
TABLE 133    JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    149
TABLE 134    JAPAN: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    150
12.4.2    CHINA    150
12.4.2.1    Healthcare infrastructure improvements to support the market growth for sepsis diagnostics in China    150
TABLE 135    CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    151
TABLE 136    CHINA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    151
12.4.3    INDIA    152
12.4.3.1    Increasing patient population and the rising number of surgical procedures to drive the market growth in India    152
TABLE 137    INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    153
TABLE 138    INDIA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    153
12.4.4    AUSTRALIA    153
12.4.4.1    The increasing number of sepsis treatment procedures indicates growth potential for the sepsis diagnostics market in Australia    153
TABLE 139    AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    154
TABLE 140    AUSTRALIA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    154
12.4.5    SOUTH KOREA    155
12.4.5.1    Rising healthcare spending to support the market
 growth in South Korea    155
TABLE 141    SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
 2019–2026 (USD MILLION)    155
TABLE 142    SOUTH KOREA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    156
12.4.6    THE REST OF ASIA PACIFIC (ROAPAC)    156
TABLE 143    ROAPAC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    157
TABLE 144    ROAPAC: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    157
12.5    LATIN AMERICA    157
TABLE 145    LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    158
TABLE 146    LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    158
TABLE 147    LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT,
 2019–2026 (USD MILLION)    159
TABLE 148    LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
2019–2026 (USD MILLION)    159
TABLE 149    LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE,
 2019–2026 (USD MILLION)    159
TABLE 150    LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE,
2019–2026 (USD MILLION)    160
TABLE 151    LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER,
2019–2026(USD MILLION)    160
12.5.1    BRAZIL    160
12.5.1.1    Brazil accounted for the largest share of the LATAM market in 2020 owing to the ongoing investments by manufacturers in the country    160
TABLE 152    BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
 2019–2026 (USD MILLION)    161
TABLE 153    BRAZIL: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
 BY TYPE, 2019–2026 (USD MILLION)    161
12.5.2    MEXICO    161
12.5.2.1    Rising medical tourism to support the market growth in Mexico    161
TABLE 154    MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    162
TABLE 155    MEXICO: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY TYPE, 2019–2026 (USD MILLION)    162
12.5.3    THE REST OF LATIN AMERICA (ROLATAM)    163
TABLE 156    ROLATAM: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)    163
TABLE 157    ROLATAM: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    163
12.6    MIDDLE EAST & AFRICA    164
12.6.1    HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS DRIVES SEPSIS OCCURRENCE IN THE MEA REGION    164
TABLE 158    MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)    165
TABLE 159    MIDDLE EAST & AFRICA: SEPSIS DAIGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)    165
TABLE 160    MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)    166
TABLE 161    MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD,
 2019–2026 (USD MILLION)    166
TABLE 162    MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2019–2026 (USD MILLION)    166
TABLE 163    MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)    167
TABLE 164    MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2019–2026(USD MILLION)    167
13    COMPETITIVE LANDSCAPE    168
13.1    OVERVIEW    168
13.2    KEY PLAYER STRATEGIES    169
13.3    REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS    170
13.4    MARKET SHARE ANALYSIS (2020)    170
TABLE 165    SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION    170
13.5    COMPETITIVE LEADERSHIP MAPPING    172
13.5.1    STARS    172
13.5.2    PERVASIVE PLAYERS    172
13.5.3    EMERGING LEADERS    173
13.5.4    PARTICIPANTS    173
FIGURE 33    SEPSIS DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020    173
13.6    COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)    174
13.6.1    PROGRESSIVE COMPANIES    174
13.6.2    STARTING BLOCKS    174
13.6.3    RESPONSIVE COMPANIES    174
13.6.4    DYNAMIC COMPANIES    174
FIGURE 34    SEPSIS DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020    175
13.7    FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET    176
TABLE 166    PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET    176
TABLE 167    PRODUCT FOOTPRINT OF COMPANIES    177
TABLE 168    REGIONAL FOOTPRINT OF COMPANIES    178
13.8    COMPETITIVE SCENARIO    179
13.8.1    SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS    179
TABLE 169    KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS, JANUARY 2018–DECEMBER 2021    179
13.8.2    SEPSIS DIAGNOSTICS MARKET: DEALS    179
TABLE 170    KEY DEALS, JANUARY 2018–DECEMBER 2021    179
13.8.3    SEPSIS DIAGNOSTICS MARKET: OTHER DEVELOPMENTS    180
TABLE 171    OTHER KEY DEVELOPMENTS, JANUARY 2018–DECEMBER 2021    180
14    COMPANY PROFILES    181
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1    BIOMÉRIEUX    181
TABLE 172    BIOMÉRIEUX.: BUSINESS OVERVIEW    181
FIGURE 35    BIOMÉRIEUX: COMPANY SNAPSHOT (2020)    182
TABLE 173    BIOMÉRIEUX.: PRODUCT OFFERINGS    183
14.2    BECTON, DICKINSON, AND COMPANY    186
TABLE 174    BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW    186
FIGURE 36    BECTON, DICKINSON, AND COMPANY: COMPANY SNAPSHOT (2020)    187
TABLE 175    BECTON, DICKINSON AND COMPANY: PRODUCT OFFERINGS    188
14.3    DANAHER CORPORATION    190
TABLE 176    DANAHER CORPORATION: BUSINESS OVERVIEW    190
FIGURE 37    DANAHER CORPORATION: COMPANY SNAPSHOT (2020)    191
TABLE 177    DANAHER CORPORATION: PRODUCT OFFERINGS    192

14.4    T2 BIOSYSTEMS    194
TABLE 178    T2 BIOSYSTEMS: BUSINESS OVERVIEW    194
FIGURE 38    T2 BIOSYSTEMS: COMPANY SNAPSHOT (2020)    194
TABLE 179    T2 BIOSYSTEMS: PRODUCT OFFERINGS    195
14.5    LUMINEX    197
TABLE 180    LUMINEX: BUSINESS OVERVIEW    197
FIGURE 39    LUMINEX: COMPANY SNAPSHOT (2020)    198
TABLE 181    LUMINEX: PRODUCT OFFERINGS    199
14.6    F. HOFFMANN-LA ROCHE AG    200
TABLE 182    F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW    200
FIGURE 40    F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)    201
TABLE 183    F. HOFFMANN-LA ROCHE AG: PRODUCT OFFERINGS    201
14.7    THERMO FISHER SCIENTIFIC    203
TABLE 184    THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW    203
FIGURE 41    THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)    204
TABLE 185    THERMO FISHER SCIENTIFIC: PRODUCT OFFERINGS    205
14.8    BRUKER CORPORATION    206
TABLE 186    BRUKER CORPORATION: BUSINESS OVERVIEW    206
FIGURE 42    BRUKER CORPORATION: COMPANY SNAPSHOT (2020)    207
TABLE 187    BRUKER CORPORATION: PRODUCT OFFERINGS    207
14.9    ABBOTT LABORATORIES    209
TABLE 188    ABBOTT LABORATORIES: BUSINESS OVERVIEW    209
FIGURE 43    ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)    210
TABLE 189    ABBOTT LABORATORIES: PRODUCT OFFERINGS    210
14.10    QUIDEL CORPORATION    211
TABLE 190    QUIDEL CORPORATION: BUSINESS OVERVIEW    211
FIGURE 44    QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)    212
TABLE 191    QUIDEL CORPORATION: PRODUCT OFFERINGS    212
14.11    SIEMENS HEALTHINEERS    213
TABLE 192    SIEMENS HEALTHINEERS: BUSINESS OVERVIEW    213
FIGURE 45    SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)    214
TABLE 193    SIEMENS HEALTHINEERS: PRODUCT OFFERINGS    214
14.12    EKF DIAGNOSTICS    216
TABLE 194    EKF DIAGNOSTICS: BUSINESS OVERVIEW    216
FIGURE 46    EKF DIAGNOSTICS: COMPANY SNAPSHOT (2020)    217
TABLE 195    EKF DIAGNOSTICS: PRODUCT OFFERINGS    217
14.13    SYSMEX CORPORATION    219
TABLE 196    SYSMEX CORPORATION: BUSINESS OVERVIEW    219
FIGURE 47    SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)    220
TABLE 197    SYSMEX CORPORATION: PRODUCT OFFERINGS    220

14.14    SEEGENE, INC.    222
TABLE 198    SEEGENE, INC.: BUSINESS OVERVIEW    222
TABLE 199    SEEGENE, INC: PRODUCT OFFERINGS    222
14.15    RESPONSE BIOMEDICAL CORP.    223
TABLE 200    RESPONSE BIOMEDICAL CORP.: BUSINESS OVERVIEW    223
TABLE 201    RESPONSE BIOMEDICAL CORP.: PRODUCT OFFERINGS    223
14.16    OTHER COMPANIES    224
14.16.1    ALIFAX S.R.L.    224
14.16.2    BODITECH MED INC.    225
14.16.3    ADVANDX    225
14.16.4    IMMUNEXPRESS INC.    226
14.16.5    AXIS-SHIELD DIAGNOSTICS    227
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15    APPENDIX    228
15.1    DISCUSSION GUIDE    228
15.2    KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL    233
15.3    AVAILABLE CUSTOMIZATIONS    235
15.4    RELATED REPORTS    235
15.5    AUTHOR DETAILS    236"